QUARK PHARMACEUTICALS INC
Autonomous AI platform that interprets customer support issues and recommends resolutions automatically
- Sector
- Software
- Headquarters
- FREMONT, CA
- Latest Form D
- $10M, Jun 2010
- Total capital
- $10M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $10M
- 1 Form D · last Jun 2010
- 197 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 18
- 6 pending · first 2016
- Rank in peer group#79 of 2705
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$10M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 2705 peers
Line = medianSoftware · Platform
- Granted patents#79 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Carlos D. Benaim, M.Sc.Executive OfficerNamed in SEC Form D filings
- Daniel Zurr, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Elena Feinstein, Ph.D.Executive OfficerNamed in SEC Form D filings
- James D. Thompson, Ph.D.Executive OfficerNamed in SEC Form D filings
- Juliana Friedmann, M.Sc.Executive OfficerNamed in SEC Form D filings
- Kazuyuki B. MatsuiDirectorNamed in SEC Form D filings
Show all 15 people
- Peter A. Thompson, M.D.DirectorNamed in SEC Form D filings
- Philip M. HahnDirectorNamed in SEC Form D filings
- Philip B. SimonDirectorNamed in SEC Form D filings
- Rami SkaliterExecutive OfficerNamed in SEC Form D filings
- Robert L. JonesExecutive OfficerNamed in SEC Form D filings
- Shai Erlich, Ph.D.Executive OfficerNamed in SEC Form D filings
- Smadar ShakkedExecutive OfficerNamed in SEC Form D filings
- Toru B. MioDirectorNamed in SEC Form D filings
- Trent M. GunterDirectorNamed in SEC Form D filings
What it has protected
USPTO · 18 granted of 24- GrantedDouble-stranded Oligonucleotide Molecules Targeting P53 And Methods Of Use ThereofUSPTOUS 10,781,449
- GrantedDouble-Stranded RNA Compounds to CASP2 and Uses ThereofUSPTOUS 10,570,394
- GrantedSirna Compounds Comprising Terminal SubstitutionsUSPTOUS 10,494,631
Show all 24 patent records
- Double-stranded Oligonucleotide Molecules Targeting P53 And Methods Of Use ThereofSep 22, 2020 · US 10,781,449Granted
- Double-Stranded RNA Compounds to CASP2 and Uses ThereofFeb 25, 2020 · US 10,570,394Granted
- Sirna Compounds Comprising Terminal SubstitutionsDec 3, 2019 · US 10,494,631Granted
- Double-stranded Oligonucleotide Molecules To DDIT4 And Methods Of Use ThereofSep 24, 2019 · US 10,421,962Granted
- Double Stranded Oligonucleotide Compounds Comprising Positional ModificationsDec 4, 2018 · US 10,144,928Granted
- Methods And Compositions For Preventing Ischemia Reperfusion Injury In OrgansOct 25, 2018 · Application 15832334Pending
- Composition Of ANTI-ENDO180 Antibodies And Methods Of Use For The Treatment Of Cancer And Fibrotic DiseasesJun 12, 2018 · US 9,993,567Granted
- Double-stranded Oligonucleotide Molecules To P53 And Methods Of Use ThereofApr 3, 2018 · US 9,932,578Granted
- Methods And Compositions For Preventing Ischemia Reperfusion Injury In OrgansJan 16, 2018 · US 9,868,953Granted
- Methods For Treating Eye DisordersOct 26, 2017 · Application 15645751Pending
- Oligonucleotide Modulators Of The Toll-like Receptor PathwayOct 24, 2017 · US 9,796,979Granted
- Methods and Compositions for NeuroprotectionAug 22, 2017 · US 9,738,896Granted
- METHODS OF TREATING OCULAR DISEASES OR DISORDERS WITH siRNASAug 10, 2017 · Application 15267651Pending
- Methods For Treating Eye DisordersJul 11, 2017 · US 9,701,961Granted
- Sirna Compounds Comprising Terminal SubstitutionsJul 11, 2017 · US 9,701,960Granted
- Double-stranded Oligonucleotide Molecules To DDIT4 And Methods Of Use ThereofApr 4, 2017 · US 9,611,474Granted
- Methods And Compositions For Preventing Ischemia Reperfusion Injury In OrgansMar 23, 2017 · Application 15312425Pending
- METHODS OF TREATING ISCHEMIA-REPERFUSION INJURY WITH siRNAsSep 20, 2016 · US 9,446,062Granted
- Combination Therapy For Treating Hearing And Balance DisordersSep 6, 2016 · US 9,434,946Granted
- Double-stranded Rna Compounds To CASP2 And Uses ThereofJul 5, 2016 · US 9,382,542Granted
- Oligoribonucleotides And Methods Of Use Thereof For Treatment Of Alopecia, Acute Renal Failure And Other DiseasesMay 10, 2016 · US 9,334,499Granted
- Oligonucleotide Compounds Comprising Non-nucleotide OverhangsFeb 2, 2016 · US 9,249,414Granted
- Combination Therapy For Treating Hearing And Balance DisordersDec 11, 2014 · Application 14367939Pending
- Methods And Compositions For Preventing Ischemia Reperfusion Injury In OrgansApplication PCTUS2015032499Pending
Related companies, and why
- Music Is Not LtdSimilar federal contract value in Software · null in contracts
- BodiData, Inc.Similar federal contract value in Software · null in contracts
- Metis Machine LLCSimilar federal contract value in Software · null in contracts
- Rockfish, Inc.Similar federal contract value in Software · null in contracts
- Prose Holding Company, LLCSimilar federal contract value in Software · null in contracts
- Automate IO Inc.Similar federal contract value in Software · null in contracts
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .